Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate‐risk prostate cancer at high risk of distant recurrence and cancer‐specific mortality

Undetectable End of Radiation PSA (EOR‐PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate‐risk (UIR) and favorable intermediate‐risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR‐PSA could further risk stratify UIR men for survival.

[1]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[2]  D. Song,et al.  End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer , 2016, Prostate Cancer and Prostatic Diseases.

[3]  Ronald C. Chen,et al.  Evaluation of the effectiveness of adding androgen deprivation to modern dose‐escalated radiotherapy for men with favorable intermediate‐risk prostate cancer , 2016, Cancer.

[4]  Y. Yamada,et al.  Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. , 2015, The Journal of urology.

[5]  D. Tindall,et al.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. , 2015, Cancer research.

[6]  A. D'Amico,et al.  Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate‐risk disease , 2015, Cancer.

[7]  A. D'Amico,et al.  Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. , 2015, JAMA oncology.

[8]  D. Song,et al.  End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation for prostate cancer. , 2015 .

[9]  A. Renshaw,et al.  The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate‐risk disease , 2014, Cancer.

[10]  Y. Yamada,et al.  A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. , 2013, European urology.

[11]  M. Zelefsky,et al.  Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes. , 2013, International journal of radiation oncology, biology, physics.

[12]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[13]  D. Kuban,et al.  Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? , 2011, International journal of radiation oncology, biology, physics.

[14]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[15]  Christopher J Kane,et al.  Prostate Cancer, Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  D. Kuban,et al.  Clinical Investigation : Genitourinary Cancer PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era , 2022 .